AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lineage Cell Therapeutics Reports Positive 36-Month Phase 1/2a Results for RG6501 in OpRegen Trial
ByAinvest
Tuesday, Sep 23, 2025 7:28 pm ET1min read
Lineage Cell Therapeutics, Inc. (LCTX) reported positive 36-month Phase 1/2a results for its OpRegen therapy, showing sustained vision improvements in patients with geographic atrophy, a form of age-related macular degeneration. The company also treated its first chronic spinal cord injury patient in a new OPC1 trial and partnered with William Demant Invest A/S to develop a cell transplant program for sensorineural hearing loss. LCTX holds $42.3 million in cash and continues to invest in R&D and manufacturing capabilities.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet